Intravenous levosimendan-norepinephrine combination during off-pump coronary artery bypass grafting in a hemodialysis patient with severe myocardial dysfunction

Journal of Cardiothoracic Surgery

Volumn 5, Issue 1, 2010, Pages

  Papadopoulos, Georgios ^a   Baikoussis, Nikolaos G ^a   Tzimas, Petros ^a   Siminelakis, Stavros N ^a   Karanikolas, Menelaos ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; NORADRENALIN; PYRIDAZINE DERIVATIVE; SIMENDAN;

ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY OBSTRUCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OFF PUMP CORONARY SURGERY; RENAL REPLACEMENT THERAPY;

ADRENERGIC ALPHA-AGONISTS; CARDIOTONIC AGENTS; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS, OFF-PUMP; CORONARY STENOSIS; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NOREPINEPHRINE; PYRIDAZINES; RENAL DIALYSIS;

EID: 77951175499     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-5-9     Document Type: Article

References (17)

1. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996, 279:120-127.
2. Levijoki J, Pollesello P, Kaivola J, Tilgmann C, Sorsa T, Annila A, Kilpelainen I, Haikala H. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000, 32:479-491. 10.1006/jmcc.1999.1093, 10731446.
3. Simdax - Levosimendan 2.5 mg/mL injection concentrate - Data Sheet. 2009, New Zealand, New Zealand Medicines and Medical Devices Safety Authority, a Business Unit of the Ministry of Health, 1-10-2010.., http://www.medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.htm
4. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297:1883-1891. 10.1001/jama.297.17.1883, 17473298.
5. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999, 288:316-325.
6. Keheninen P, Haikala H. Increases in diastolic coronary flow by Levosimendan and pinacidil are differently mediated through opening of the ATP-sensitive potassium channels. J Amer Coll Cardiol 1998, 31:154.
7. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000, 52:213-217. 10.1211/0022357001773715, 10714952.
8. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997, 283:375-383.
9. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005, 11:435-455. 10.2174/1381612053382043, 15725064.
10. Puttonen J, Kantele S, Ruck A, Ramela M, Hakkinen S, Kivikko M, Pentikainen PJ. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J Clin Pharmacol 2008, 48:445-454. 10.1177/0091270007313390, 18303124.
11. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, Pentikainen PJ. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004, 57:412-415. 10.1111/j.1365-2125.2003.02043.x, 1884479, 15025738.
12. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 2005, 46:830-835. 10.1097/01.fjc.0000189076.71730.f1, 16306809.
13. Raftopoulos SC. Levosimendan following coronary artery bypass grafting in a patient with end-stage renal failure: a case report. Crit Care Resusc 2004, 6:109-112.
14. Sandell EP, Antila S, Koistinen IL. The effects of renal failure on the pharmacokinetics of levosimendan [abstract]. 1st Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 1995,
15. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998, 36:446-449.
16. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995, 27:1859-1866. 10.1016/0022-2828(95)90009-8, 8523447.
17. Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995, 26(Suppl 1):S70-S76.